Carlos V. Paya Sells 13,014 Shares of Immune Design Corp (IMDZ) Stock

Immune Design Corp (NASDAQ:IMDZ) CEO Carlos V. Paya sold 13,014 shares of the company’s stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $1.58, for a total transaction of $20,562.12. Following the sale, the chief executive officer now owns 169,590 shares in the company, valued at $267,952.20. The sale was disclosed in a filing with the SEC, which is available at this link.

Immune Design stock opened at $1.52 on Wednesday. The stock has a market capitalization of $72.25 million, a P/E ratio of -0.87 and a beta of 2.43. Immune Design Corp has a 1-year low of $1.10 and a 1-year high of $5.05.

Immune Design (NASDAQ:IMDZ) last issued its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.29) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.03. The business had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.75 million. Immune Design had a negative net margin of 2,409.84% and a negative return on equity of 43.44%. As a group, equities research analysts predict that Immune Design Corp will post -1.14 earnings per share for the current fiscal year.

IMDZ has been the topic of a number of recent analyst reports. HC Wainwright set a $8.00 price objective on shares of Immune Design and gave the stock a “buy” rating in a research report on Wednesday, November 7th. Leerink Swann lowered shares of Immune Design from an “outperform” rating to a “market perform” rating in a research report on Friday, October 12th. Zacks Investment Research raised shares of Immune Design from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a research report on Friday, November 30th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $11.00 price objective on shares of Immune Design in a research report on Friday, October 12th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $7.13.

Several large investors have recently modified their holdings of IMDZ. Vanguard Group Inc boosted its holdings in shares of Immune Design by 0.7% in the 3rd quarter. Vanguard Group Inc now owns 1,615,442 shares of the biotechnology company’s stock valued at $5,574,000 after buying an additional 11,006 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Immune Design in the 3rd quarter valued at $36,000. Nexthera Capital LP acquired a new position in shares of Immune Design in the 3rd quarter valued at $146,000. Renaissance Technologies LLC acquired a new position in shares of Immune Design in the 3rd quarter valued at $508,000. Finally, Bridgeway Capital Management Inc. boosted its holdings in shares of Immune Design by 172.1% in the 3rd quarter. Bridgeway Capital Management Inc. now owns 221,192 shares of the biotechnology company’s stock valued at $763,000 after buying an additional 139,900 shares in the last quarter. 46.27% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Carlos V. Paya Sells 13,014 Shares of Immune Design Corp (IMDZ) Stock” was first reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.thestockobserver.com/2019/01/09/carlos-v-paya-sells-13014-shares-of-immune-design-corp-imdz-stock.html.

About Immune Design

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.

Recommended Story: Using the New Google Finance Tool

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply